Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

References

  1. 1.

    Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108:djv439.

  2. 2.

    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.

    CAS  Article  Google Scholar 

  3. 3.

    Varade J, Magadan S, Gonzalez-Fernandez A. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol. 2021;18:805–28.

    CAS  Article  Google Scholar 

  4. 4.

    Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:332.

    PubMed  Google Scholar 

  5. 5.

    Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:166.

    PubMed  Google Scholar 

  6. 6.

    Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18:792–804.

    CAS  Article  Google Scholar 

  7. 7.

    Dai X, Mei Y, Cai D, Han W. Standardizing CAR-T therapy: getting it scaled up. Biotechnol Adv. 2019;37:239–45.

    CAS  Article  Google Scholar 

  8. 8.

    Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol. 2021;18:2083–100.

    CAS  Article  Google Scholar 

  9. 9.

    Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D. Driving the CAR to the bone marrow transplant program. Curr Hematol Malig Rep. 2019;14:561–9.

    Article  Google Scholar 

  10. 10.

    Han W, Fu X. Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital. Sci China Life Sci. 2016;59:1063–7.

    Article  Google Scholar 

  11. 11.

    Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;5:134.

    CAS  Article  Google Scholar 

  12. 12.

    McGrath E, Chabannon C, Terwel S, Bonini C, Kuball J. Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Curr Opin Oncol. 2020;32:427–33.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by funds from the National Natural Science Foundation of China (No. 31991171, 81830002, 31870873, 81830006, and 81830004), the Science Technology Department of Zhejiang Province (No. 2021C03117) and the China Postdoctoral Science Foundation (No. 2021M690184 and 2021M690186).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Wenbin Qian, Aibin Liang or Weidong Han.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, X., Dai, H., Li, X. et al. Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cell Mol Immunol 19, 122–124 (2022). https://doi.org/10.1038/s41423-021-00789-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-021-00789-3

Search

Quick links